Fertility-sparing treatment for overweight patients with early-stage endometrial cancer or atypical endometrial hyperplasia under weight loss intervention

针对超重且患有早期子宫内膜癌或非典型子宫内膜增生的患者,在减重干预下进行保留生育功能的治疗

阅读:2

Abstract

OBJECTIVE: To evaluate various body fat indicators under weight management on the time to complete response (CR) in overweight patients undergoing fertility-sparing treatment for endometrial cancer (EC) or atypical hyperplasia (AEH). METHODS: Clinical data and weight indicators of obese patients (percent body fat ≥ 30%) with AEH or early-stage EC who received fertility-sparing treatment from 2018 to 2023 were retrospectively collected from the Peking Union Medical College Hospital. Cox proportional hazards regression analysis was used for univariate and multivariate analyses. RESULTS: Fifty-three patients with AEH (45.28%) or EC (54.72%) were finally included. Percent body fat > 8% (p = 0.018) was identified as an independent predictor of time to CR. Patients with body fat mass loss > 15%, and percent body fat loss > 8% had a lower recurrence rate (p = 0.043 and p = 0.007, respectively). Patients with visceral fat area loss > 18%, body fat mass loss > 15%, and percent body fat loss > 8% had a slightly higher pregnancy rate. CONCLUSION: When overweight patients with AEH or EC receive fertility-sparing treatment, multiple body fat indicators, especially the loss of percent body fat, are more meaningful for evaluating the time to CR, recurrence rate, and pregnancy rate than weight loss. Registration: ChiCTR2200067099

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。